• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

    29.70 -0.27 (-0.90%)
    Streaming Delayed Price Updated: 10:09 AM EST, Nov 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about NewAmsterdam Pharma Company N.V. - Warrant

    < Previous 1 2 3 Next >
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
    – NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – 
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Host R&D Day on June 11, 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
    Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers 
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.